BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 25581727)

  • 1. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
    Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
    Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelioid GBMs show a high percentage of BRAF V600E mutation.
    Kleinschmidt-DeMasters BK; Aisner DL; Birks DK; Foreman NK
    Am J Surg Pathol; 2013 May; 37(5):685-98. PubMed ID: 23552385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.
    Tosuner Z; Geçer MÖ; Hatiboğlu MA; Abdallah A; Turna S
    Oncol Lett; 2018 Aug; 16(2):2402-2408. PubMed ID: 30013630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adult classical glioblastoma with a BRAF V600E mutation.
    Takahashi Y; Akahane T; Sawada T; Ikeda H; Tempaku A; Yamauchi S; Nishihara H; Tanaka S; Nitta K; Ide W; Hashimoto I; Kamada H
    World J Surg Oncol; 2015 Mar; 13():100. PubMed ID: 25885250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF-V600E immunohistochemistry in a large series of glial and glial-neuronal tumors.
    Breton Q; Plouhinec H; Prunier-Mirebeau D; Boisselier B; Michalak S; Menei P; Rousseau A
    Brain Behav; 2017 Mar; 7(3):e00641. PubMed ID: 28293477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
    Matsumura N; Nakajima N; Yamazaki T; Nagano T; Kagoshima K; Nobusawa S; Ikota H; Yokoo H
    Neuropathology; 2017 Feb; 37(1):58-63. PubMed ID: 27302309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
    Dvorak K; Higgins A; Palting J; Cohen M; Brunhoeber P
    Pathol Oncol Res; 2019 Jan; 25(1):349-359. PubMed ID: 29127628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.
    Ihle MA; Fassunke J; König K; Grünewald I; Schlaak M; Kreuzberg N; Tietze L; Schildhaus HU; Büttner R; Merkelbach-Bruse S
    BMC Cancer; 2014 Jan; 14():13. PubMed ID: 24410877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of osteoclast-like giant cell-rich epithelioid glioblastoma with BRAF V600E mutation.
    Funata N; Nobusawa S; Yamada R; Shinoura N
    Brain Tumor Pathol; 2016 Jan; 33(1):57-62. PubMed ID: 26602910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.
    Dono A; Vu J; Anapolsky M; Hines G; Takayasu T; Yan Y; Tandon N; Zhu JJ; Bhattacharjee MB; Esquenazi Y; Ballester LY
    J Neurooncol; 2020 Sep; 149(3):463-472. PubMed ID: 33009979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma.
    Kuroda J; Nobusawa S; Nakamura H; Yokoo H; Ueda R; Makino K; Yano S; Kuratsu J
    Neuropathology; 2016 Apr; 36(2):181-6. PubMed ID: 26375727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.
    Tetzlaff MT; Pattanaprichakul P; Wargo J; Fox PS; Patel KP; Estrella JS; Broaddus RR; Williams MD; Davies MA; Routbort MJ; Lazar AJ; Woodman SE; Hwu WJ; Gershenwald JE; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2015 Aug; 46(8):1101-10. PubMed ID: 26058727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations.
    Na JI; Kim JH; Kim HJ; Kim HK; Moon KS; Lee JS; Lee JH; Lee KH; Park JT
    Virchows Arch; 2015 Aug; 467(2):155-68. PubMed ID: 25894433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
    Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
    Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
    Lasota J; Kowalik A; Wasag B; Wang ZF; Felisiak-Golabek A; Coates T; Kopczynski J; Gozdz S; Miettinen M
    Am J Surg Pathol; 2014 Sep; 38(9):1235-41. PubMed ID: 24832158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
    Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J
    Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].
    Lyu JJ; Kong YY; Cai X; Shen XX; Lu YW; Ren M
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):548-552. PubMed ID: 28810295
    [No Abstract]   [Full Text] [Related]  

  • 18. Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy.
    Kanemaru Y; Natsumeda M; Okada M; Saito R; Kobayashi D; Eda T; Watanabe J; Saito S; Tsukamoto Y; Oishi M; Saito H; Nagahashi M; Sasaki T; Hashizume R; Aoyama H; Wakai T; Kakita A; Fujii Y
    Acta Neuropathol Commun; 2019 Jul; 7(1):119. PubMed ID: 31345255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.
    Rössle M; Sigg M; Rüschoff JH; Wild PJ; Moch H; Weber A; Rechsteiner MP
    Virchows Arch; 2013 Nov; 463(5):623-31. PubMed ID: 24085553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry.
    Jabbar KJ; Luthra R; Patel KP; Singh RR; Goswami R; Aldape KD; Medeiros LJ; Routbort MJ
    Am J Surg Pathol; 2015 Apr; 39(4):454-61. PubMed ID: 25634750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.